Region-specific induction of δFosB by repeated administration of typical versus atypical antipsychotic drugs

Synapse

Volumn 33, Issue 2, 1999, Pages 118-128

  Atkins, Joshua B ^a   Chlan Fourney, Jennifer ^b   Nye, Heather E ^a   Hiroi, Noboru ^a,c   Carlezon Jr , William A ^a   Nestler, Eric J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Clozapine; Fos; FRA (Fos related antigen); Haloperidol; Nucleus accumbens; Olanzapine; Prefrontal cortex; Risperidone; Striatum

Indexed keywords

CLOZAPINE; DOPAMINE RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PROTEIN; RISPERIDONE; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; CAUDATE NUCLEUS; DRUG EXPOSURE; EXTRAPYRAMIDAL SYMPTOM; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; NUCLEUS ACCUMBENS; ONCOGENE C FOS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; PUTAMEN; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BLOTTING, WESTERN; CAUDATE NUCLEUS; CLOZAPINE; DRUG ADMINISTRATION SCHEDULE; HALOPERIDOL; IMMUNOHISTOCHEMISTRY; MALE; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PROTO-ONCOGENE PROTEINS C-FOS; PUTAMEN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0033566277     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199908)33:2<118::AID-SYN2>3.0.CO;2-L     Document Type: Article

References (66)

1. Arnt J, Skarsfeldt T. 1998. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101.
2. Brene S, Messer CJ, Nestler EJ. 1998. Expression of mRNAs encoding ionotropic glutamate receptors in rat brain: regulation by haloperidol. Neuroscience. 84:813-823.
3. Bunney BS. 1992. Clozapine: a hypothesized mechanism for its unique clinical profile. Br J Psychiatry 160(suppl. 17):17-21.
4. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT. 1996. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14: 87-96.
5. Chen JS, Nye HE, Kelz MB, Hiroi N, Nakabeppu Y, Hope BT, Nestler EJ. 1995. Regulation of ΔFosB and FosB-like proteins by electroconvulsive seizure (ECS) and cocaine treatments. Mol Pharmacol 48:880-889.
6. Chen J, Kelz MB, Hope BT, Nakabeppu Y, Nestler EJ. 1997. Chronic FRAs: stable variants of ΔFosB induced in brain by chronic treatments. J Neurosci 17:4933-4941.
7. Costall B, Naylor RJ. 1995. Behavioural interactions between 5-hydroxytryptophan, neuroleptic agents and 5-HT receptor antagonists in modifying rodent responding to aversive situations. Br J Pharmacol 116:2989-2999.
8. Creese I, Burt DR, Snyder SH. 1976. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483.
9. Deutch AY, Duman RS. 1996. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization. Neuroscience 70:377-389.
10. Deutch AY, Lee MC, Iadorola MJ. 1992. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 3:332-341.
11. Deutch AY, Ongur D, Duman RS. 1995. Antipsychotic drugs induce Fos protein in the thalamic paraventricular nucleus: a novel locus of antipsychotic drug action. Neuroscience 66:337-246.
12. Doucet J-P, Nakabeppu Y, Bedard PJ, Hope BT, Nestler EJ, Jasmin B, Chen JS, Iadarola MJ, St-Jean M, Wigle N, Blanchet P, Grondin R, Robertson GS. 1996. Chronic alterations in dopaminergic neurotrans-mission produce a persistent elevation of striatal ΔFosB expression. Eur J Neurosci 8:365-381.
13. Dragunow M, Robertson GS, Faul RLM, Robertson HA, Jansen K. 1990. D2 dopamine receptor antagonists induce Fos and related proteins in rat striatal neurons. Neuroscience 37:287-294.
14. Durcan MJ, Rigdon GC, Norman MH, Morgan PF. 1995. Is clozapine selective for the dopamine D4 receptor? Life Sci 57:PL275-283.
15. Eastwood SL, Porter RH, Harrison PJ. 1996. The effect of chronic haloperidol treatment on glutamate receptor subunit (GluR1 GluR2 KA1 KA2 NR1. mRNAs and glutamate binding protein mRNA in rat forebrain. Neurosci Lett 212:163-166.
16. Fibiger HC. 1994. Neuroanatomical targets of neuroleptic drugs as revealed by Fos immunochemistry. J Clin Psychiatry 55(suppl. B):33-36.
17. Fitzgerald LW, Deutch AY, Gasic G, Heinemann SF, Nestler EJ. 1995. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J Neurosci 15:2453-2461.
18. Hiroi N, Graybiel AM. 1996. Atypical and typical neuroleptic treatments induce distinct programs of transcription factor expression in the striatum. J Comp Neurol 374:70-83.
19. Hiroi N, Brown J, Haile C, Ye H, Greenberg ME, Nestler EJ. 1997. FosB mutant mice: loss of chronic cocaine induction of Fos-related proteins and heightened sensitivity to cocaine's psychomotor and rewarding effects. Proc Natl Acad Sci USA 94:10397-10402.
20. Hiroi N, Brown J Ye H, Saudou F, Vaidya VA, Duman RS, Greenberg ME, Nestler EJ. 1998. Essential role of the FosB gene in molecular, cellular, and behavioral actions of electroconvulsive seizures. J Neurosci 18:6952-6962.
21. Hope B, Kosofsky B, Hyman SE, Nestler EJ. 1992. Regulation of IEG expression and AP-1 binding by chronic cocaine in the rat nucleus accumbens. Proc Natl Acad Sci USA 89:5764-5768.
22. Hope BT, Kelz MB, Duman RS, Nestler EJ. 1994a. Chronic electroconvulsive seizure (ECS) treatment results in expression of a long-lasting AP-1 complex in brain with altered composition and characteristics. J Neurosci 14:4318-4328.
23. Hope BT, Nye HE, Kelz MB, Self DW, Iadarola MJ, Nakabeppu Y, Duman RS, Nestler EJ. 1994b. Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron 13:1235-1244.
24. Hyman SE, Nestler EJ. 1996. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 153: 151-162.
25. Ishibashi T, Ikeda K, Ishida K, Yasui J, Tojima R, Nakamura M, Ohno Y. 1996. Contrasting effects of SM-9018, a potential atypical antipsychotic, and haloperidol on c-fos mRNA expression in the rat striaturn. Eur J Pharmacol 303:247-251.
26. Janssen PAJ, Niemegeers CJE, Awouters F, Schellekens KH, Megens AA, Meert TF. 1988. Pharmacology of risperidone (R 64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244:685-693.
27. Karin M, Liu Z, Zandi E. 1997. AP-1 function and regulation. Curr Opin Cell Biol 9:240-246.
28. Kinon BJ, Lieberman JA. 1996. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 124: 2-34.
29. Kosten TA, Nestler EJ. 1994. Clozapine attenuates conditioned place preference to cocaine. Life Sci 55:PL9-PL14.
30. Kosten TA, DeCaprio JL, Nestler EJ. 1996. Long-term haloperidol administration enhances and short-term administration attenuates the behavioral effects of cocaine in a place conditioning procedure. Psychopharmacology 128:304-312.
31. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PA. 1988. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661-670.
32. Lopez-Gimenez JF, Mengod G, Palacios JM, Vilaro MT. 1997. Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100,907. Naunyn Schmiedebergs Arch Pharmacol 356:446-454.
33. Mandelzys A, Gruda MA, Bravo R, Morgan JI. 1997. Absence of a persistently elevated 37 kDa fos-related antigen and AP-1-like DNA-binding activity in the brains of kainic acid-treated FosB null mice. J Neurosci 17:5407-5415.
34. Mansbach RS, Brooks EW, Sanner MA, Zorn SH. 1998. Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition. Psychopharmacology 135:194-200.
35. Marder SR, Meibach RC. 1994. Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835.
36. Meador-Woodruff JF, King RE, Damask SP, Bovenkerk KA. 1996. Differential regulation of hippocampal AMPA and kainate receptor subunit expression by haloperidol and clozapine. Mol Psychiatry 1:41-53.
37. Meltzer HY. 1996. Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. Br J Psychiatry Suppl. (29):23-31.
38. Meltzer HY, Fibiger HC. 1996. Olanzapine: a new typical antipsychotic drug. Neuropsychopharmacology 14:83-85.
39. Meshul CK, Bunker GL, Mason JN, Allen C, Janowsky A. 1996. Effects of subchronic clozapine and haloperidol on striatal glutamatergic synapses. J Neurochem 67:1965-1973.
40. Miller JC. 1990. Induction of c-fos mRNA expression in the rat striatum by neuroleptic drugs. J Neurochem 54:1453-1455.
41. Morgan JI, Curran T. 1991. Stimulus-transcription coupling in the nervous system: involvememnt of the inducable proto-oncogenes fos and jun. Annu Rev Neurosci 14:421-451.
42. Morgan JI, Curran T. 1995. Immediate-early genes: ten years on. Trends Neurosci 18:66-67.
43. Nakabeppu Y, Nathans D. 1991. A naturally occurring truncated form of FosB that inhibits Fos/Jun transcriptional activity. Cell 64:751-759.
44. Nestler EJ, Kelz MB, Chen JS. 1999. ΔFosB: a molecular mediator of long-term neural and behavioral plasticity. Brain Res (in press).
45. Nguyen TV, Kasofsky B, Birnbaum R, Cohen BM, Hyman SE. 1992. Differential expression of c-fos and Zif-268 in rat striatum following haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci USA 89:4270-4274.
46. Nomikos GG, Tham CS, Fibiger HC, Svensson TH. 1997. The putative atypical antipsychotic drug amperozide preferentially increases c-fos expression in rat medial prefrontal cortex and lateral septum. Neuropsychopharmacology 17:197-201.
47. Nye HE, Nestler EJ. 1996. Induction of chronic Fos-related antigens in rat brain by chronic morphine administration. Mol Pharmacol 49:636-645.
48. Nye H, Hope BT, Kelz M, Iadarola M, Nestler EJ. 1995. Pharmacological studies of the regulation by cocaine of chronic Fra (Fos-related antigen) induction in the striatum and nucleus accumbens. J Pharmacol Exp Ther 275:1671-1680.
49. Pennypacker KR, Hong JS, McMillian MK. 1995. Implications of prolonged expression of Fos-related antigens. Trends Pharmacol Sci 16:317-321.
50. Pickar D, Breier A. 1989. Clinical and biochemical effects of neuroleptic treatment: implications for the pathophysiology of schizophrenia. In: Schulz SC, Tamminga CA, editors. Schizophrenia: scientific progress. New York: Oxford University Press. p 285-301.
51. Reynolds GP. 1997. What is an atypical antipsychotic? J Psychopharmacol 11:195-199.
52. Robertson GS, Fibiger HC. 1992. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46:315-328.
53. Robertson GS, Matsubura H, Fibiger HC. 1994. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271:1058-1066.
54. Seeman P, Lee T, Chau-Wong M, Wong K. 1976. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-719.
55. Seeman P, Corbett R, Van Tol HH. 1997. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 16:93-110.
56. Self DW, Barnhart WJ, Lehman DA, Nestler EJ. 1996. Opposite modulation of cocaine-seeking behavior by D1-like and D2-like dopamine receptor agonists. Science 271:1586-1589.
57. Skarsfeldt T. 1995. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 281:289-294.
58. Stern RG, Kahn R, Harvey PD, Amin F, Apter SH, Hirschowitz J. 1993. Early response to haloperidol treatment in chronic schizophrenia. SchizophrRes 10:165-171.
59. Stockton ME, Rasmussen K. 1996. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 14:97-104.
60. Tang L, Todd RD, Heller A, O'Malley KL. 1994. Pharmacological and functional characterization of D2 D3, and D4 dopamine receptors in fibroblast and dopaminergic cell lines. J Pharmacol Exp Ther 268:495-502 (see erratum: 270:1397).
61. Vahid-Ansari F, Nakabeppu Y, Robertson GS. 1996. Contrasting effects of chronic clozapine, seroquel (ICI204,636) and haloperidol administration on ΔFosB-like immunoreactivity in the rodent forebrain. Eur J Neurosci 8:927-936.
62. Waddington JL. 1995. The clinical psychopharmacology of antipsychotic drugs in schizophrenia. In: Hirsch SR, Weinberger DR, editors. Schizophrenia. Cambridge MA: Blackwell Science, p 341-357.
63. Wan W, Ennulat DJ, Cohen BM. 1995. Acute administration of typical and atypical drugs induces distinctive patterns of Fos expression in the rat forebrain. Brain Res 688:95-104.
64. Widnell KL, Self DW, Lane SB, Russell DS, Vaidya V, Miserendino MJD, Rubin CS, Duman RS, Nestler EJ. 1996. Regulation of CREB expression: in vivo evidence for a functional role in morphine action in the nucleus accumbens. J Pharmacol Exp Ther 276:306-315.
65. Wise RA, Mendrek A, Carlezon WA Jr. 1996. MK-801 (dizocilpine): synergist and conditioned stimulus in bromocriptine-induced psychomotor sensitization. Synapse 22:362-368.
66. Young ST, Porrino LJ, Iadarola MJ. 1991. Cocaine induces striatal c-Fos-immunoreactive protein via Dl receptors. Proc Natl Acad Sci USA 88:1291-1295.